Crystalline AAK1 Inhibitor Phosphate Salt for Stable Scale-Up
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthetic approaches for AAK1 inhibitors like (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine are not suitable for large-scale manufacture due to issues with stability, solubility, and impurities, posing challenges for safe and effective pharmaceutical formulations.
Innovation Solution
Development of a crystalline form of the AAK1 inhibitor (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-aminium dihydrogen phosphate (Compound K), which is thermally stable and has suitable solubility for pharmaceutical use, along with methods for its large-scale production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing synthetic approaches are used for AAK1 inhibitors, then the compound can be prepared on small laboratory scale, but it is not suitable for large-scale manufacture due to stability and solubility issues
Solution Approach 1:
The patent applies parameter changes by converting the compound into different salt forms (phosphate, sulfate, hydrochloride, hydrobromide, mesylate, trifluoroacetate salts) with modified physical and chemical parameters. This transformation resolves the contradiction by maintaining the core molecular structure while altering solubility and stability characteristics to enable large-scale manufacture.
Solution Approach 2:
The patent creates composite material systems by forming salt complexes of the AAK1 inhibitor with various counterions. These composite salt forms combine the active pharmaceutical ingredient with suitable anions to achieve optimal stability and solubility profiles for pharmaceutical formulation and large-scale production.
2Productivity
If existing synthetic approaches are used for AAK1 inhibitors, then the compound can be prepared on small laboratory scale, but it has impurity issues that pose challenges for safe and effective pharmaceutical formulations
Solution Approach 1:
By changing the chemical form to specific salt structures, the patent improves purification efficiency and reduces impurity carryover during scale-up. The salt formation process provides better crystallization behavior and separation characteristics, enabling more effective removal of synthesis byproducts and impurities.
3Ease of manufacture
If existing synthetic approaches are used for AAK1 inhibitors, then the compound can be prepared, but it has solubility issues that pose challenges for pharmaceutical formulations
Solution Approach 1:
The patent systematically modifies solubility parameters by forming salts with different counterions (phosphate, sulfate, hydrochloride, hydrobromide, mesylate, trifluoroacetate). Each salt form presents different solubility characteristics, allowing selection of the optimal form for specific pharmaceutical formulation requirements and administration routes.
Data Source
AI summary
Salts of the AAK1 inhibitor (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and solid forms thereof are disclosed, as are pharmaceutical formulations comprising them and methods of their preparation.